60 Degrees Pharmaceuticals $SXTP: Commercial-Stage Infectious Disease Biotech with FDA-Approved ARAKODA® Reports Q1 Results 60 Degrees Pharmaceuticals reported Q1 2026 results, highlighting a revenue-generating biotech platform anchored by ARAKODA®, its FDA-approved malaria prevention product commercially available in the U.S. and Australia. Key Q1 2026 Investor Takeaways: • $162K in net product revenue, remaining relatively stable year-over-year • FDA-approved ARAKODA® continues to provide a commercial foundation • Active focus on infectious diseases and vector-borne illness, a global healthcare category with long-term relevance • U.S. and Australia commercial availability expands the company’s international footprint For biotech investors, $SXTP stands out as an emerging infectious disease company with an approved product already on the market, existing revenue, and a focused strategy in a specialized healthcare niche. Read the full Q1 2026 results: $SXTP $GDRX $VRTX $LLY $NVO $PFE $VALN $REGN